Angiopoietins as serum biomarkers for lymphatic anomalies
- 18 December 2016
- journal article
- research article
- Published by Springer Nature in Angiogenesis
- Vol. 20 (1) , 163-173
Abstract
Vascular anomalies can cause significant morbidity and mortality. Advances in diagnosis will be improved if noninvasive biomarkers can be identified, as obtaining a tissue biopsy can worsen the disease and precipitate complications. The goal of this study was to identify biomarkers for vascular anomaly patients to aid diagnosis and potentially give insights into pathogenesis. Blood was collected at baseline and then 6 and 12 months after treatment with the mTOR inhibitor sirolimus. Patients groups included generalized lymphatic anomaly (GLA), kaposiform lymphangiomatosis (KLA) and kaposiform hemangioendothelioma (KHE) with or without the Kasabach–Merritt phenomenon (KMP) coagulopathy. Serum was obtained from healthy controls selected to match the age and sex of the patients (21 days–28.5 years; 42% males; 58% females). Angiogenic and lymphangiogenic factors (VEGF-A, C, D, Ang-1 and Ang-2) were measured in serum using ELISA. In lymphatic anomaly patients, baseline levels of VEGF-A and VEGF-D were not different compared to controls. Angiopoietin-2 (Ang-2) levels were near controls levels in GLA patients but 10-fold greater in KLA patients and 14-fold greater in KHE patients when the KMP coagulopathy was present but not when it was absent. VEGF-C and angiopoietin-1 (Ang-1) levels were lower in KHE patients with KMP. Our analyses suggest that Ang-2 and Ang-1 can be used as biomarkers to help identify KLA and KHE patients with KMP coagulopathy with high sensitivity and specificity. After 12 months of sirolimus treatment, Ang-2 levels were lower in KLA and KHE with KMP patients compared to baseline levels and with most patients showing a clinical response. Hence, serum Ang-2 and Ang-1 levels may help in the diagnosis of patients with lymphatic anomalies and are concordant to sirolimus response.Keywords
Funding Information
- FDA (5RO1FD003712-04)
- Lymphatic Malformation Institute (2015)
This publication has 33 references indexed in Scilit:
- Kaposiform Hemangioendothelioma: Atypical Features and Risks of Kasabach-Merritt Phenomenon in 107 ReferralsThe Journal of Pediatrics, 2013
- Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon: From Vincristine to SirolimusKlinische Padiatrie, 2012
- Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)Blood, 2012
- VEGF-D: a modifier of embryonic lymphangiogenesisBlood, 2008
- Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient miceDevelopmental Biology, 2008
- Regulation of lymphangiogenesis—From cell fate determination to vessel remodelingExperimental Cell Research, 2006
- Excess Circulating Angiopoietin-2 May Contribute to Pulmonary Vascular Leak in Sepsis in HumansPLOS Medicine, 2006
- Increased Expression of Urinary Matrix Metalloproteinases Parallels the Extent and Activity of Vascular AnomaliesPediatrics, 2005
- Angiopoietin-2 Is Required for Postnatal Angiogenesis and Lymphatic Patterning, and Only the Latter Role Is Rescued by Angiopoietin-1Developmental Cell, 2002
- Increased Tie2 Expression, Enhanced Response to Angiopoietin-1, and Dysregulated Angiopoietin-2 Expression in Hemangioma-Derived Endothelial CellsThe American Journal of Pathology, 2001